Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Adaptive Biotechnologies reports robust Q4 performance and eyes growth opportunities

Adaptive Biotechnologies delivered strong financial performance in Q4 2022 and full-year 2022, driven by growth in MRD and immune medicine segments, showcasing operational efficiency and revenue expansion.
While facing challenges such as paused T-Detect commercialization and revenue phasing complexities, the company is well-positioned to capitalize on opportunities like market acceptance of MRD and drug discovery partnerships.
With a positive revenue outlook for 2023, supported by strategic initiatives and a strong cash position, Adaptive Biotechnologies is poised for continued growth and market leadership in the biotechnology sector.

Adaptive Biotechnologies reports robust Q1 revenue and growth prospects

Adaptive Biotechnologies showcased strong revenue growth and operational improvements in Q1 2023.
The company is strategically positioned to capitalize on opportunities in MRD business and immune medicine segment.
Challenges include potential impacts from regulatory changes and the need for milestone achievements.
Overall, Adaptive Biotechnologies remains focused on growth, innovation, and expanding its market presence.

Adaptive Biotechnologies reports revenue growth and strategic partnerships in Q2

Adaptive Biotechnologies demonstrated solid revenue growth and margin improvement in Q2 2023, with a strategic outlook for future profitability.
Strong partnerships with Genentech and advocacy for MRD as a clinical endpoint position the company for continued success in the market.
Ongoing challenges in pricing and integration efforts are being addressed, while opportunities in drug discovery and AI-driven target discovery offer growth potential.

Adaptive Biotechnologies reports Q3 revenue growth amidst industry challenges

Adaptive Biotechnologies saw mixed performance with MRD growth and Immune Medicine decline.
Company's focus on MRD profitability and novel target identification shows strategic strength.
Facing challenges from industry softening and cost pressures but eyeing revenue growth opportunities.
Maintaining long-term target of $1,600 in 2027 while making progress towards profitability.

Adaptive Biotechnologies reports mixed Q4 results, focuses on MRD growth

Adaptive Biotechnologies navigated a transformative year in 2023, with a strong focus on MRD and Immune Medicine businesses. The company faces challenges in Immune Medicine revenue decline and achieving profitability. Strategic initiatives and partnerships position the company for growth and innovation in the biotechnology sector.

Adaptive Biotechnologies posts solid Q1 results, eyes breakeven targets

Adaptive Biotechnologies reported strong MRD revenue growth and aims to reduce operating expenses significantly in 2024. Despite a net loss, the company updated full-year guidance with a focus on achieving breakeven targets by 2025 and 2026. Opportunities lie in MRD segment expansion and immune medicine development.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Illumina

One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.

Better Buy: Illumina vs. Adaptive Biotechnologies

Carvana

Datadog

In the midst of a global market meltdown, I'm buying virtual companies that are winning market share.

3 Stocks I'm Buying Right Now

This biotech is seeking to understand the immune system to develop insights and drug products for the most vexing health problems, including COVID-19.

1 Recent IPO to Add to Your Watch List

SEATTLE, April  09, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the addition of two prominent hires to its executive leadership team. Mark Adams, Ph.D. has been appointed Chief Technical Officer to advance technology strategy across the company. Jyoti Palaniappan joins as Senior Vice President, Clinical Diagnostics, immunoSEQ Dx to establish the commercial infrastructure for the diagnostics pipeline resulting from our partnership with Microsoft.

Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx

Axsome Therapeutics

Adaptive Biotechnologies and Axsome Therapeutics are under-followed stocks with large upsides.

2 Top Stocks That Aren't On  Wall Street's Radar

Amgen

Despite a potential vaccine, the novel coronavirus could return on a seasonal basis, much like the flu, according to Seattle-based company Adaptive Biotechnologies.

Adaptive Biotech’s deal with Amgen influenced by belief that COVID-19 may return seasonally, like flu

The two biotechs aren't wasting any time getting their new joint COVID-19 effort up and running.

Amgen Teams Up With Adaptive Biotechnologies to Develop COVID-19 Therapy

Pharmaceutical giant Amgen is aiming to develop a new drug to treat and prevent COVID-19, using insights from Seattle-based Adaptive Biotechnologies’ system for sequencing the human immune system, under an expanded partnership announced by the companies Thursday morning.

The search for a COVID-19 cure: Amgen and Adaptive Biotech partner in quest for new drug

Shares of Amgen Inc. AMGN, -0.17% gained 1.2% in trading on Thursday after the drugmaker announced that it is collaborating with Adaptive Biotechnologies Corp.

Amgen, Adaptive Biotechnologies ink COVID-19 antibody development collaboration

Microsoft (MSFT) extends partnership with Adaptive Biotechnologies on an open source dataset to aid the development of a diagnostic vaccine for COVID-19.

Microsoft, Adaptive Biotech Collaborate to Fight COVID-19

Microsoft

The companies teamed up in early 2018 to try to map how the immune system responds to various diseases. Next on their agenda: SARS-CoV-2.

Microsoft and Adaptive Biotechnologies' Immune System Partnership Takes on Coronavirus

Microsoft and Seattle-based Adaptive Biotechnologies announced Friday they will work together to map the immune response to COVID-19.

Microsoft and Adaptive Biotechnologies partner to study immune response to COVID-19

Microsoft, Adaptive Biotechnologies, Illumina and other companies are partnering on a project to map out how the human immune system responds to the virus. Most efforts, they say, are focused on the biology of the virus.

Microsoft and Adaptive Biotechnologies are studying how the human immune system reacts to the coronavirus

Amazon

Avalara Inc

Expedia

Impinj

Redfin

Smartsheet

T-Mobile US

Zillow

The Dow Jones closed down more than 2,000 points, or 7.8%. The S&P 500 fell 7.6%. International markets also took a hit.

Shares of Seattle tech companies sink as stock market sees worst drop since 2008

Adaptive Biotechnologies' (ADPT) CEO Chad Robins on Q4 2019 Results - Earnings Call Transcript

Adaptive (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Adaptive (ADPT)

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed last week he trimmed the firm’s Adaptive Biotechnologies Corp.

Andreas Halvorsen Trims Adaptive Biotechnologies Stake

The two companies hope to decode the human immune system.

Why Is Microsoft Investing in Adaptive Biotechnologies?

The genetic diagnostics company announced the pricing of a common stock offering that suggests there's solid demand for shares.

Here's Why Adaptive Biotechnologies Is Soaring Today

SEATTLE, Jan.  23, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders at a public offering price of $26.50 per share, before underwriting discounts and commissions. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. Adaptive will not receive any proceeds from the sale of the shares of common stock by the selling shareholders. The offering is expected to close on January 28, 2020, subject to customary closing conditions.

Adaptive Announces Pricing of Public Offering of Common Stock

Seattle-based Adaptive Biotechnologies plans to sell up to 9.

Adaptive Biotechnologies plans to sell up to 9.2M shares; revenue grew 52% in 2019

SEATTLE, Jan.  21, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders. In addition, certain selling shareholders expect to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock in the offering. Adaptive will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling shareholders. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Adaptive Announces Proposed Public Offering of Common Stock

SEATTLE, Jan.  21, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today preliminary unaudited revenue for the full year 2019.

Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019

SEATTLE, Jan.  13, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global diagnostic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax in the registrational Phase III CRISTALLO (CO41685) study for the treatment of newly diagnosed people with chronic lymphocytic leukemia (CLL) plus additional future venetoclax studies in CLL. Adaptive and Genentech will partner to incorporate the clonoSEQ Assay to measure MRD status as a primary endpoint in this registrational study. Under the terms of the agreement, Adaptive will receive upfront and sample testing payments to advance the development and potential expedited approval of venetoclax in this setting.

Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

SEATTLE, Jan.  08, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its MolDX program, has expanded coverage of the clonoSEQ Assay to include monitoring minimal residual disease (MRD) in Medicare patients with chronic lymphocytic leukemia (CLL). This adds to existing Medicare coverage in B-cell acute lymphoblastic leukemia (ALL) and multiple myeloma, which was established in January 2019. Medicare coverage for clonoSEQ is aligned with clinical practice guidelines in covered disease states which support assessing MRD at multiple time points throughout therapy to monitor treatment response and help predict patient outcomes. This expanded coverage policy is effective immediately and continues the positive momentum for clonoSEQ with over 175M lives covered to date.

News for Adaptive Biotechnologies Stock (ADPT)